

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1

Fanglei Zuo¹, Ph.D., Rui Sun¹, M.S., Hassan Abolhassani¹, Ph.D., Likun Du¹, Ph.D., Yating Wang¹, M.S., Stelios Vlachiotis¹, M.S., Federico Bertoglio², Ph.D., Maren Schubert², Ph.D., Nima Rezaei³, Ph.D., Zahra Chavoshzadeh⁴, M.D., Concetta Guerra⁵, Ph.D., Andrea Cavalli⁵, Ph.D., Juni Andréll⁶, Ph.D., Makiko Kumagai-Braesch⁷, Ph.D., Yintong Xue⁸, Ph.D., Yunlong Cao^{9,10}, Ph.D., Michael Hust², Ph.D., Davide F. Robbiani⁵, Ph.D., Xiaoliang Sunney Xie^{9,10}, Ph.D., Lennart Hammarström^{1#}, Ph.D., Harold Marcotte^{1#}, Ph.D., Qiang Pan-Hammarström^{1#}, Ph.D.

¹*Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.*

²*Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics; Departments of Biotechnology and Medical Biotechnology, Braunschweig, Germany.*

³*Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.*

⁴*Pediatric Infections Research Center, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.*

⁵*Institute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.*

⁶*Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden.*

⁷*Division of Transplantation Surgery, CLINTEC, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden.*

⁸*Department of Immunology, Peking University Health Science Center, Beijing, P.R. China.*

⁹*Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P.R. China.*

¹⁰*Changping Laboratory, Beijing, P.R. China.*

These authors jointly supervised this work

Leading contact: qiang.pan-hammarstrom@ki.se

32 **Abstract**

33 The emergence of highly immune-escape Omicron variants of the severe acute respiratory syndrome coronavirus
34 2 (SARS-CoV-2), such as BQ and XBB, has led to concerns about the efficacy of vaccines. Using
35 lentivirus-based pseudovirus neutralizing assay, we showed that heterologous vaccination involving parental
36 mRNA vaccine as a booster or second booster in individuals that received two or three doses of inactivated
37 vaccines strongly augments the neutralizing activity against emerging Omicron subvariants, including BF.7,
38 BQ.1.1, and XBB.1, by 4.3- to 219-folds. Therefore, a heterologous boosting strategy with mRNA-based
39 vaccines should be considered in populations where inactivated vaccines were primarily used.

42 **Text**

43 The emergence of highly immune-escape Omicron variants of the severe acute respiratory syndrome coronavirus
44 2 (SARS-CoV-2) has led to concerns about the efficacy of vaccines and therapeutic monoclonal antibodies.
45 Omicron subvariants BA.4.6, BF.7, BQ.1.1, XBB, and XBB.1 harbor the spike protein R346T substitution which
46 contributes to evasion of class III anti-spike monoclonal antibody recognition while XBB, and XBB.1.1
47 subvariants harbor the F486S substitution which reduces binding for class I and II monoclonal antibodies.¹ BQ.1,
48 BQ.1.1, XBB, and XBB.1 are increasing rapidly in the United States, India, Europe, and other parts of the world,
49 whereas BF.7 is one of the dominant strains currently circulating in China. Due to humoral immune imprinting, a
50 phenomenon in which initial exposure to the original strain of SARS-CoV-2, by infection or vaccination, limits a
51 person's future immune response against variants, the bivalent vaccine booster and hybrid immunity may not
52 provide sufficient protection against emerging Omicron subvariants.²⁻⁴ We have previously shown that an mRNA
53 vaccine booster in individuals vaccinated with two doses of inactivated vaccine significantly increased the level
54 of plasma neutralizing antibodies against Omicron BA.1.⁵ Whether this vaccination strategy retains neutralizing
55 activity against the emerging Omicron subvariants remains unknown.

56
57 We used enzyme-linked immunosorbent assay and lentivirus-based pseudovirus neutralizing assay (see the
58 Supplementary Methods section in the Supplementary Appendix), to evaluate the levels of binding and
59 neutralizing antibodies in 77 plasma samples collected from 67 healthy volunteers within 1-5 months after
60 vaccination or infection (Table S1). The participants were grouped based on their vaccination and infection
61 history: three doses of inactivated vaccine; three doses of mRNA vaccine; two doses of inactivated vaccine
62 followed by an mRNA vaccine booster; three doses of inactivated vaccine followed by one or two doses of
63 mRNA vaccine booster; infected during the G614 wave and sampled after one or two subsequent doses of
64 mRNA vaccine; and breakthrough infection during the Omicron BA.1 wave.

65
66 In all six groups, the level of receptor-binding domain (RBD)-specific IgG and the neutralizing activity were
67 lower against all Omicron subvariants tested than the original G614 strain, with the lowest level measured
68 against the XBB.1 subvariant (Fig. S1, Fig. 1, and Fig. S2). The level of specific IgG and half-maximal
69 pseudovirus neutralization titers (NT50) against Omicron subvariants in the heterologous vaccination groups
70 were significantly higher than that in individuals receiving three doses of a homologous inactivated vaccine,

71 reaching a level similar to those who received three doses of homologous mRNA-vaccine or a boost of mRNA
72 vaccine after infection or experienced breakthrough infection (Fig. S1 and Fig. 1). The NT50 of heterologous
73 vaccination groups were 155- to 158-folds higher against G614 and 4.3- to 219-folds higher against Omicron
74 subvariants than that of three doses of a homologous inactivated vaccine group (Fig. 1). Although the median
75 NT50 values of each vaccinated/infected group against BF.7, BQ.1.1, and XBB.1 were 4- to 148-fold lower
76 compared to that against G614, the median NT50 values against these Omicron subvariants were 17 to 512 in the
77 heterologous vaccination groups as well as homologous mRNA vaccine group, while those in three doses of a
78 homologous inactivated vaccine group were below the limit of detection (Fig. S2B) and may account for the
79 surge of COVID-19 cases in China where inactivated vaccines are mainly used.

80

81 Thus, among all omicron subvariants tested, the lowest neutralization activity elicited by vaccines and BTI was
82 against BQ.1.1, and XBB.1. Our results suggest that heterologous vaccination involving parental mRNA vaccine
83 as a booster or second booster in individuals that received two/three doses of inactivated vaccines strongly
84 augments the neutralizing activity and may still be effective against emerging Omicron subvariants. Therefore, a
85 heterologous boosting strategy with mRNA-based vaccines should be considered in populations where
86 inactivated vaccines were primarily used.

87 **Acknowledgments**

88 This work was supported by The European Union’s Horizon 2020 research and innovation program (ATAC,
89 101003650, D.F.R., M.H., L.H., H.M., Q.P.H), the Center for Innovative Medicine at the Karolinska Institutet
90 (FoUI-963219, Q.P.H), the Swedish Research Council (2019-01302, 2020-06116, Q.P.H), the Knut and Alice
91 Wallenberg Foundation (KAW2020.0102, L.H., Q.P.H), and the Magnus Bergvalls Stiftelse (2022-111, F.Z).

92

93 **Competing interests**

94 The authors declare no competing interests.

95

96 **References**

- 97 1. Qu, P., Evans, J.P., Faraone, J.N., et al. Enhanced neutralization resistance of SARS-CoV-2 Omicron
98 subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. *Cell Host Microbe* 2023;**31**:9-17.
99 doi.org/10.1016/j.chom.2022.11.012
- 100 2. Kurhade, C., Zou, J., Xia, H., et al. Low neutralization of SARS-CoV-2 Omicron BA. 2.75. 2, BQ. 1.1,
101 and XBB. 1 by parental mRNA vaccine or a BA. 5-bivalent booster. *Nat Med* 2022;
102 doi.org/10.1038/s41591-022-02162-x.
- 103 3. Cao, Y., Jian, F., Wang, J., et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron
104 RBD evolution. *Nature* 2022; doi.org/10.1038/s41586-022-05644-7.
- 105 4. Wang, Q., Bowen, A., Valdez, R., et al. Antibody Response to Omicron BA.4–BA.5 Bivalent Booster. *N*
106 *Engl J Med* 2023; [doi: 10.1056/NEJMc2213907](https://doi.org/10.1056/NEJMc2213907).
- 107 5. Zuo, F., Abolhassani, H., Du, L., et al. Heterologous immunization with inactivated vaccine followed by
108 mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. *Nat Commun* 2022;**13**,
109 2670. doi.org/10.1038/s41467-022-30340-5


110

111

All rights reserved. No reuse allowed without permission.

112 **Figure 1. Plasma neutralization activity against G614 and Omicron subvariants.**

113 Plasma neutralization activity against the G614 strain of severe acute respiratory syndrome coronavirus 2
 114 (SARS-CoV-2) (panel A) and the Omicron subvariants BA.2 (panel B), BA.4/5 (panel C), BF.7 (panel D),
 115 BQ.1.1 (panel E), and XBB.1 (panel F) in participants who received three doses (3X) of inactivated vaccine (n =
 116 13), three doses of mRNA vaccine (n = 14), two doses (2X) of inactivated vaccine followed by an mRNA
 117 vaccine booster (n = 16), three doses of inactivated vaccine followed by one or two doses of mRNA vaccine
 118 booster (n = 5; 8 samples), one or two doses of mRNA vaccine after infection (G614 wave) (Infected plus mRNA
 119 vaccine, n = 9; 11 samples) or had experienced breakthrough infection during the Omicron BA.1 wave
 120 (Breakthrough infection, n = 15). The median half-maximal neutralization titers (NT50) and the ratio of the
 121 NT50 titer of each group versus the group who received three doses of inactivated vaccine are shown on the top
 122 of each panel. Symbols represent individual samples and horizontal black lines indicate the median. Whiskers
 123 indicate the interquartile range. A two-sided Mann–Whitney U test was used to compare the neutralizing activity
 124 between three doses of inactivated vaccine group and other groups in each panel. The dashed line indicates the
 125 limit of detection.



126

127

128 **Supplementary Appendix**

129

130

131 **Table of contents**

132

133 Methods.....7

134 Study design.....7

135 Production of SARS-CoV-2 RBD protein7

136 Detection of antibodies specific to SARS-CoV-2.....7

137 Neutralization assay against pseudotyped SARS-CoV-2.....8

138 Quantification and statistical analysis.....8

139 Data availability8

140 References.....9

141 Table S1. Demographic data of vaccinated individuals.....10

142 Figure S1. Level of specific IgG antibodies against the receptor binding domain (RBD) of the G614
143 strain and Omicron subvariants.....11

144 Figure S2. Level of receptor binding domain (RBD)-specific IgG antibodies (A) and neutralization
145 activity (B) against G614 strain and Omicron subvariants12

146

147

148 **Methods**

149

150 **Study design**

151 Study inclusion criteria included subjects being above 18 years of age who have received inactivated and/or
152 mRNA vaccines with a documented vaccination history (type of vaccine, number of doses, the interval between
153 the doses, days after the latest dose, if they have been infected), and who were willing and able to provide written
154 informed consent. The study included 77 samples from 67 healthy volunteers (64% females, median age of 31
155 years) during 2021-2022 who received three doses of inactivated vaccine CoronaVac (Sinovac) or BBIBP-CorV
156 (Sinopharm), or three doses of an mRNA vaccine BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna), or
157 a combination of both (two doses of inactivated vaccine followed by one or two doses of heterologous mRNA
158 boost; or three doses of inactivated vaccine followed by one or two doses of heterologous mRNA boost), some of
159 whom had experienced breakthrough infections during the Omicron BA.1 wave. Samples were collected 9-144
160 days (median day 48) after dose three of inactivated vaccine, 11-121 days (median day 28.5) after each mRNA
161 vaccine dose including after mRNA heterologous boost, and 11-43 days (median day 23) after a breakthrough
162 infection (Supplementary Appendix Table 1). Infection was confirmed when an individual tested positive for
163 antigen or qPCR test. Plasma samples from pre-vaccinated, non-infected healthy donors from our cohort (n = 12,
164 Supplementary Appendix Table 1) were also collected as negative controls and used to calculate the cutoff value
165 of the ELISA method. The study was approved by the ethics committees in institutional review board (IRB) of
166 Stockholm, and the Tehran University of Medical Sciences.

167

168 **Production of SARS-CoV-2 RBD protein**

169 The RBDs of G614 and Omicron (BA.1, BA.2, BA.4/5) variants were ordered as GeneString from GeneArt
170 (Thermo Fisher Scientific). All sequences of the RBD (aa 319-541 in GenBank: MN908947) were inserted into
171 an *NcoI/NotI* compatible variant of an OpiE2 expression vector carrying the N-terminal signal peptide of the
172 mouse Ig heavy chain and a C-terminal 6×His-tag. RBD of G614 and Omicron were expressed in a
173 baculovirus-free expression system in High Five insect cells and purified on HisTrap Excel columns (Cytiva)
174 followed by size-exclusion chromatography on 16/600 Superdex 200-pg columns (Cytiva).^{1,2} The RBDs of
175 Omicron BQ.1.1 and XBB/XBB.1 were ordered from Sino Biologicals.

176

177 **Detection of antibodies specific to SARS-CoV-2**

178 For assessing the anti-RBD IgG binding activity, high-binding Corning Half area plates (Corning #3690) were
179 coated overnight at 4°C with RBD derived from the G614 and Omicron BA.1, BA.2, BA.4/5, BQ.1.1, and
180 XBB/XBB.1 (1.7 µg/ml) variants in PBS. Serial dilutions of plasma in 0.1% BSA in PBS were added and plates
181 were subsequently incubated for 1.5 h at room temperature. Plates were then washed and incubated for 1 h at
182 room temperature with horseradish peroxidase (HRP)-conjugated goat anti-human IgG (Invitrogen #A18805)
183 (diluted 1:15 000 in 0.1% BSA-PBS). Bound antibodies were detected using tetramethylbenzidine substrate
184 (Sigma #T0440). The color reaction was stopped with 0.5M H₂SO₄ after 10 min incubation and the absorbance
185 was measured at 450 nm using an ELISA plate reader. For each sample, the EC₅₀ values were calculated using
186 GraphPad Prism 7.04 software and expressed as relative potency towards an internal calibrant for which the

187 Binding Antibody Unit (BAU) was calculated using the WHO International Standard 20/136 in relation to the
188 G614 RBD. The positive cutoff was calculated as 2 standard deviations (2SD) above the mean of a pool of
189 pre-vaccination samples (n = 12).

190

191 **Neutralization assay against pseudotyped SARS-CoV-2**

192 The human-codon optimized gene coding for the S protein of G614, BA.2, and BA.4/5 lacking the C-terminal 19
193 codons (S Δ 19) was synthesized by GenScript. The S Δ 19 gene of BF.1, BQ.1.1, and XBB.1 were constructed by
194 site-directed mutagenesis (QuikChange Multi Site-Directed Mutagenesis Kit, Agilent) using BA.2 or BA.4/5
195 S Δ 19 gene as a template. To generate (HIV-1/NanoLuc2AEGFP)-SARS-CoV-2 particles, three plasmids were
196 used, with a reporter vector (pCCNanoLuc2AEGFP), HIV-1 structural/regulatory proteins (pHIVNLGagPol) and
197 SARS-CoV-2 S Δ 19 carried by separate plasmids as previously described.³ 293FT cells were transfected with 7
198 μ g of pHIVNLGagPol, 7 μ g of pCCNanoLuc2AEGFP, and 2.5 μ g of a pSARS-CoV-2-S Δ 19 carrying the S Δ 19
199 gene from G614 or Omicron variants (at a molar plasmid ratio of 1:1:0.45) using 66 μ l of 1 mg/ml
200 polyethylenimine (PEI).

201

202 Five-fold serially diluted plasma samples were incubated with pseudotyped SARS-CoV-2 virus (G614, BA.2,
203 BA.4/5, BF.7, BQ.1.1, and XBB.1) for 1 h at 37 °C. The mixture was subsequently incubated with
204 ACE2-expressing HEK293T cells for analyses of G614 or Omicron pseudoviruses for 48 h, after which the cells
205 were washed with PBS and lysed with Luciferase Cell Culture Lysis reagent (Promega). NanoLuc luciferase
206 activity in the lysates was measured using the Nano-Glo Luciferase Assay System (Promega) with a Tecan
207 Infinite microplate reader. The relative luminescence units were normalized to those derived from cells infected
208 with the pseudotyped virus in the absence of plasma samples. The NT50 values for plasma were determined
209 using four-parameter nonlinear regression (the least squares regression method without weighting) (GraphPad
210 Prism 7.04 software).

211

212 **Quantification and statistical analysis**

213 Microsoft Excel 2017 was used for data collection for this study. Two-sided Mann–Whitney U test was
214 performed for comparisons of anti-SARS-CoV-2 binding and neutralizing antibody levels between groups. A
215 Wilcoxon matched-pairs signed rank test was used for the comparison of paired samples. All analyses and data
216 plotting were performed with GraphPad 7.05. A Chi-square test for trend was used to compare the gender
217 between groups. A Kruskal-Wallis analysis of variance (ANOVA) was performed to compare the age and
218 sampling day after vaccination/infection between groups. A p-value less than 0.05 was considered to be
219 statistically significant.

220

221 **Data availability**

222 The data that support the findings of this study are available within the Article. All other data are available from
223 the corresponding author upon reasonable request.

224

225 **References**

- 226 1. Bertoglio, F., Fühner, V., Ruschig, M., et al. A SARS-CoV-2 neutralizing antibody selected from
227 COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. *Cell*
228 *Rep* 2021;**36**:109433.
- 229 2. Korn, J., Schäckermann, D., Kirmann, T., et al. Baculovirus-free insect cell expression system for high
230 yield antibody and antigen production. *Sci Rep* 2020;**10**:1–10.
- 231 3. Schmidt, F., Weisblum, Y., Muecksch, et al. Measuring SARS-CoV-2 neutralizing antibody activity using
232 pseudotyped and chimeric viruses. *J Exp Med* 2020;**217**:e20201181.
- 233
- 234

235 **Table S1. Demographic data of vaccinated individuals.**

Groups	Number of individuals	Number of samples	Male/Female	Median age (IQR) ^a , years	Median sampling day after vaccination/infection (IQR)
Before vaccination (used for cutoff calculation)	12	12	5/7	38 (28-48)	
3 doses of inactivated vaccine	13	13	6/7	31 (27-56)	48 (12-92)
3 doses of mRNA vaccine	14	14	3/11	36 (30-53)	19 (15-29)
2 doses of inactivated vaccine plus an mRNA vaccine booster	16	16	6/10	28 (26-29)	28 (19-39)
3 doses of inactivated vaccine plus mRNA vaccine booster	5	8 (4 after the first dose of mRNA vaccine and 4 after the second dose of mRNA vaccine)	1/4	28 (27-32)	31 (19-82)
Infected plus mRNA vaccine	9	11 (7 after the first dose of mRNA vaccine and 4 after the second dose of mRNA vaccine)	5/4	37 (31-52)	31 (18-37)
Breakthrough infection ^b	15	15	4/11	34 (27-53)	23 (17-34)
<i>Comparison of groups</i>			Non-significant ^c	Non-significant ^d	Non-significant ^d

236 ^a IQR: Interquartile range.


237 ^b After two or three doses of either inactivated or mRNA vaccine or a combination of both during the Omicron
238 BA.1 wave.

239 ^c Chi-square test for trend.

240 ^d Kruskal-Wallis ANOVA.

241 **Figure S1. Level of specific IgG antibodies against the receptor binding domain (RBD) of the G614 strain**
 242 **and Omicron subvariants.**

243 Level of specific IgG antibodies against the RBD of the G614 strain of severe acute respiratory syndrome
 244 coronavirus 2 (SARS-CoV-2) (panel A) and the Omicron subvariants BA.1 (panel B), BA.2 (panel C), BA.4/5
 245 (panel D), BQ.1.1 (panel E), and XBB.1 (panel F) in participants who received three doses (3X) of inactivated
 246 vaccine, three doses of mRNA vaccine, two doses (2X) of inactivated vaccine followed by an mRNA vaccine
 247 booster, three doses of inactivated vaccine followed by one or two doses of mRNA vaccine booster, one or two
 248 doses of mRNA vaccine after infection (G614 wave) (Infected plus mRNA vaccine) or had experienced
 249 breakthrough infection during the Omicron BA.1 wave (Breakthrough infection). The median antibody levels
 250 and the ratio of the antibody levels of each group versus the group who received three doses of inactivated
 251 vaccine are shown on the top of each panel. Symbols represent individual samples and horizontal black lines
 252 indicate the median. Whiskers indicate the interquartile range. A two-sided Mann–Whitney U test was used to
 253 compare the antibody levels between three doses (3X) of inactivated vaccine group and other groups in each
 254 panel. Antibody levels are presented as binding antibody units (BAU)/ml. The cutoff value (dashed line) is
 255 calculated separately for each variant from samples of 12 pre-vaccinated, non-infected individuals.




256

257


258 **Figure S2. Level of receptor binding domain (RBD)-specific IgG antibodies (A) and neutralization activity**
 259 **(B) against G614 strain and Omicron subvariants.**

260 Level of RBD-specific IgG antibodies and half-maximal neutralization titers (NT50) against the G614 strain of
 261 SARS-CoV-2 and the Omicron subvariants BA.1, BA.2, BA.4/5, BQ.1.1, and XBB/XBB.1 in participants who
 262 received three doses (3X) of inactivated vaccine, three doses of mRNA vaccine, two doses (2X) of inactivated
 263 vaccine followed by an mRNA vaccine booster, three doses of inactivated vaccine followed by one or two doses
 264 of mRNA vaccine booster, one or two doses of mRNA vaccine after infection (G614 wave) (Infected plus
 265 mRNA vaccine) or had experienced breakthrough infection during the Omicron BA.1 wave (Breakthrough
 266 infection). The median antibody levels or neutralization titer and the ratio of the antibody levels or neutralization
 267 titer against G614 strain to that against each Omicron subvariant are shown on the top of each panel. Antibody
 268 levels are presented as binding antibody units (BAU)/ml. Symbols represent individual samples and horizontal
 269 black lines indicate the median. Whiskers indicate the interquartile range. The connecting lines between the
 270 variants represent matched serum samples. A Wilcoxon matched-pairs signed rank test was used to compare the
 271 antibody levels or neutralization titers against G614 strain to that against each Omicron subvariant in each panel.
 272 The dashed line indicates the limit of detection.

A



B



273